Sellas, Catalent Pharma deal

Catalent and Sellas partnered to reprofile insomnia drug zolpidem to treat Parkinson’s disease (PD) and progressive supranuclear palsy (PSP) using Catalent’s OSDrC OptiDose drug delivery technology. C...